PCI Invests In Second Commercial Scale Contained Manufacturing Facility

PCI Tredegar is excited to announce significant investment in additional capacity and capabilities, adding to the already world-recognized Center of Excellence for the manufacturing of highly potent products.

In recent years, the strength of PCI Pharma Services has been to focus on building capacity today, based on demand predictions of the future.

PCI High Potent Market Background

In 2013, PCI opened a new, state-of-the-art Contained Manufacturing Center of Excellence. This investment was secured based on the growth in market demand for the number of potent molecules in development requiring specialist processing due to increased focus in disease areas such as oncology.

Since the launch of this facility, PCI has identified significant future demand for ongoing specialist commercial scale manufacturing and packaging services as products progress through the development to commercialization life cycle.

PCI’s response to this prediction being that in 2019, plans were released outlining the latest expansion investment set to double the commercial manufacturing capacity at the PCI Tredegar site, accompanied by an all-encompassing, commercial scale, state-of-the-art high potent packaging hall, providing a seamless link between the commercial manufacturing and packaging of these life-saving medicines.

Commercial Scale High Potent Manufacturing Expansion and Business Continuity

The commercial scale manufacturing expansion not only doubles the available capacity for new clients as products move into the commercialization stage of the product life cycle, but it also serves to provide business continuity and peace of mind for existing clients. With two separate but comparable contained manufacturing facilities on a single site PCI offers true flexibility and supply security.

Commercial Scale Fully Automated State-of-the-art High Potent Packaging Suite

The investment in the new packaging hall provides state-of-the-art automated capabilities for the commercial scale end-to-end packaging of potent products including full-online Serialization. The capabilities also include online, multi-colour HAPA foil printing for blister packaging formats, meeting the ongoing growth demand for more targeted, specialist products including orphan indications resulting in smaller runs and more complex commercial launch market needs.

Launch

The new commercial scale highly potent manufacturing and packaging facilities will be fully validated and operational by February 2022.

If you would like to hear more about these investment plans or indeed any other aspect of PCI’s strategy moving forward, please contact us at talkfuture@pciservices.com.

"We're investing in our facilities to help provide a seamless link between the commercial manufacturing and packaging of life-saving medicines."

— Rebecca Coutts PhD, General Manager, Tredegar